Dna X annual revenue
2018
2019
2020
2021
2022
2023
2024
2025
Dna X Revenue Growth & History (SONM)
Dna X reported $0 in revenue for fiscal 2025, a decrease of 100.00% from the previous fiscal year.
View full Dna X company overviewDna X annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$50.9M | −100.00% |
| 2024 | 2024-12-31 | $50.9M | −$42.7M | −45.62% |
| 2023 | 2023-12-31 | $93.6M | $23.8M | +34.09% |
| 2022 | 2022-12-31 | $69.8M | $15.3M | +27.96% |
| 2021 | 2021-12-31 | $54.6M | −$9.4M | −14.72% |
| 2020 | 2020-12-31 | $64.0M | −$52.3M | −44.95% |
| 2019 | 2019-12-31 | $116.3M | −$19.4M | −14.31% |
| 2018 | 2018-12-31 | $135.7M | — | — |
Dna X quarterly revenue
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$11.2M | −100.00% |
| Q1 2026 | 2026-03-31 | $0 | −$16.7M | −100.00% |
| Q4 2025 | 2025-12-31 | −$44.1M | −$59.4M | −389.10% |
| Q3 2025 | 2025-09-30 | $16.2M | $1.2M | +7.94% |
| Q2 2025 | 2025-06-30 | $11.2M | −$326,000 | −2.83% |
| Q1 2025 | 2025-03-31 | $16.7M | $7.6M | +83.38% |
| Q4 2024 | 2024-12-31 | $15.3M | $1.8M | +13.65% |
| Q3 2024 | 2024-09-30 | $15.0M | −$12.5M | −45.51% |
| Q2 2024 | 2024-06-30 | $11.5M | −$15.3M | −57.09% |
| Q1 2024 | 2024-03-31 | $9.1M | −$16.7M | −64.66% |
| Q4 2023 | 2023-12-31 | $13.4M | −$10.7M | −44.32% |
| Q3 2023 | 2023-09-30 | $27.6M | $7.1M | +34.49% |
| Q2 2023 | 2023-06-30 | $26.8M | $14.9M | +124.47% |
| Q1 2023 | 2023-03-31 | $25.8M | $12.5M | +94.61% |
| Q4 2022 | 2022-12-31 | $24.1M | $8.2M | +51.39% |
| Q3 2022 | 2022-09-30 | $20.5M | $6.1M | +41.90% |
| Q2 2022 | 2022-06-30 | $12.0M | $1,000 | +0.01% |
| Q1 2022 | 2022-03-31 | $13.3M | $1.0M | +8.32% |
| Q4 2021 | 2021-12-31 | $15.9M | $96,000 | +0.61% |
| Q3 2021 | 2021-09-30 | $14.4M | $52,000 | +0.36% |
| Q2 2021 | 2021-06-30 | $12.0M | −$9.1M | −43.23% |
| Q1 2021 | 2021-03-31 | $12.2M | −$466,000 | −3.67% |
| Q4 2020 | 2020-12-31 | $15.8M | −$1.3M | −7.78% |
| Q3 2020 | 2020-09-30 | $14.4M | −$14.5M | −50.11% |
| Q2 2020 | 2020-06-30 | $21.1M | −$22.7M | −51.86% |
| Q1 2020 | 2020-03-31 | $12.7M | −$13.8M | −52.02% |
| Q4 2019 | 2019-12-31 | $17.2M | −$29.4M | −63.10% |
| Q3 2019 | 2019-09-30 | $28.9M | −$10.6M | −26.96% |
| Q2 2019 | 2019-06-30 | $43.7M | $12.3M | +39.10% |
| Q1 2019 | 2019-03-31 | $26.5M | $8.3M | +45.60% |
| Q4 2018 | 2018-12-31 | $46.5M | — | — |
| Q3 2018 | 2018-09-30 | $39.5M | — | — |
| Q2 2018 | 2018-06-30 | $31.4M | — | — |
| Q1 2018 | 2018-03-31 | $18.2M | — | — |
Dna X revenue growth trends
Dna X's latest reported quarter, Q2 2026, generated $0 in revenue, a decrease of 100.00% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Dna X source filings ↗